Highest-materiality recent filing
NHI Q1 EPS +11% to $0.82 but cuts FY2026 FFO guidance to $4.74-$4.79
Net income per diluted share $0.82 (+10.8% YoY); NAREIT FFO $1.23 (+7.9%).
NHI CFO John Spaid to retire July 1, 2026; Todd Siefert named successor
John Spaid to retire as EVP/CFO/Treasurer effective July 1, 2026; no disagreement with company.
NHI sells 35 SNF/IL properties to NHC/OP for $560M; strengthens balance sheet
Purchase price $560M; 32 skilled nursing + 3 independent living facilities in 7 states.
NHI signs $560M sale of 35 SNF/IL facilities to NHC; reduces leverage, pivots to private-pay
Purchase price of $560M for 32 skilled nursing + 3 independent living facilities currently leased to NHC.
NHI files $500M at-the-market equity distribution agreement with forward sale options
Equity Distribution Agreement allows sale of up to $500M of common stock through multiple agents.
NHI Q4 Normalized FFO $1.22/share, 2026 guidance $4.94-$4.99
Q4 GAAP EPS $0.80 (vs $0.95 prior yr); NAREIT FFO $1.22; Normalized FFO $1.22 (vs $1.12).
NHI Q3 Normalized FFO $1.32/share, up 28% YoY; raises full-year guidance third time
Net income $0.69/diluted share vs $0.65 YoY; NAREIT FFO $1.09 vs $1.03.
NHI closes $350M offering of 5.350% Senior Notes due 2033
$350M aggregate principal of 5.350% Senior Notes due Feb 1, 2033 issued at 98.903% of par.
NHI gives default notice to NHC affiliate over non-monetary lease violations covering 35 properties
Default notice sent Sept 8, 2025 for non-compliance with Master Lease on 32 skilled nursing and 3 independent living facilities.
NHI Q2 Normalized FFO $1.22 beats, raises FY guidance, increases dividend
Q2 Normalized FFO per share $1.22 vs $1.18; NAREIT FFO $1.19 vs $1.18; net income $0.79 vs $0.81.
NHI Q1 EPS $0.74, NAREIT FFO $1.14; raises 2025 guidance mid-point
Net income per diluted share $0.74 vs $0.71 YoY; NAREIT FFO $1.14 vs $1.10; Normalized FFO $1.15 vs $1.12.
NHI Q4 net income $0.95/diluted share; introduces 2025 FFO guidance $4.59-$4.66
Q4 2024 NAREIT FFO per diluted share $1.24 (up from $1.09 YoY); Normalized FFO $1.12 vs $1.09.
NHI Q3 normalized FFO $1.03; cuts 2024 guidance on SLM credit loss and lower revenue
Net income per diluted share Q3 $0.65 (vs $0.68 YoY); Normalized FFO $1.03 (vs $1.08).
NHI Announces Retirement of Chairman W. Andrew Adams
W. Andrew Adams will retire as Chairperson and Board member effective December 31, 2024 after more than 30 years of leadership.
National Health Investors enters amended $700M credit agreement and amends $200M term loan
Entered $700M revolving credit facility maturing Oct 2028, with options to extend by 6 or 12 months upon fee payment.
NHI enters forward sale agreements for 2.76M shares at $68.40; expects net proceeds ~$188.3M
Underwriting agreement dated Aug 14, 2024 for 2,760,000 shares (including 360,000 option exercised) at $68.40 per share.
NHI beats Q2 expectations, raises full-year NAREIT FFO guidance to $4.50-$4.54
Net income per diluted share $0.81 vs $0.92 YoY; NAREIT FFO per share $1.18 vs $1.05 YoY.
NHI Q1 Normalized FFO $1.12/share vs $1.11 YoY; full-year guidance raised
Q1 diluted EPS $0.71 (vs $0.79); NAREIT FFO $1.10 (vs $1.16); Normalized FFO $1.12 (vs $1.11).
On March 27, 2025, National Health Investors, Inc. (the “Company” or “NHI”) announced that, upon the recommendation of its Nominating and Corporate Governance Committee, it has increased the size of the Board to eight members and has appointed Robert W. Chapin, Jr. to fill the newly created seat on the Board, effective immediately.
On February 7, 2025, Robert T. Webb notified National Health Investors, Inc. (the “Company”) of his decision to resign from his position as a member of the Board of Directors (the “Board”) effective immediately.
Appointed Ms. Todd as a member of the Special Committee related to the National HealthCare Corporation potential lease.
Appointed Ms. Todd as Chairperson of the Audit Committee;
Appointed Ms. Todd as a member of the Nominating and Corporate Governance Committee;
on December 2, 2024, the Company announced that upon the recommendation of its Nominating and Corporate Governance Committee, it has appointed Candice W. Todd to fill the soon to be vacant seat on the Board, effective January 1, 2025.
on November 5, 2024 the Company announced the retirement of Mr. W. Andrew Adams from the Board effective December 31, 2024.
W. Andrew Adams notified National Health Investors, Inc. (the “Company”) of his decision to retire from his position as Chairperson and a member of the Board of Directors (the “Board”) effective December 31, 2024.
Max materiality 0.90 · Median 0.30 · Most common event other_material